Virax Biolabs Group Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated April 21, 2023, reports a change in the Company's independent registered public accounting firm. The filing covers the period through April 19, 2023, and pertains to Virax Biolabs Group Limited, a foreign private issuer.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the administrative change of auditors.
Material Changes
- Dismissal of Auditor: The Company dismissed BF Borgers CPA PC ("BFB") effective April 19, 2023.
- Appointment of Successor: The Company appointed Reliant CPA PC ("Reliant") as the new independent registered public accounting firm effective April 19, 2023, to audit the fiscal year ended March 31, 2023.
- Audit History: BFB's reports for fiscal years 2021 and 2022 did not contain adverse opinions or disclaimers but did express doubt regarding the Company's ability to continue as a going concern.
- Disagreements: There were no disagreements with BFB on accounting principles, practices, or auditing scope during the two most recent fiscal years or through the date of dismissal.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future operations. The primary risk disclosed is the historical "going concern" doubt expressed by the former auditor in prior fiscal years. No reportable events were identified during the relevant periods.
Investor Verification Checklist
- Verify the status of the "going concern" doubt noted in the 2021 and 2022 audit reports.
- Confirm the engagement terms and scope of the new auditor, Reliant CPA PC.
- Review the letter from BF Borgers CPA PC (Exhibit 16.1) for any additional context on the dismissal.
- Monitor upcoming filings for the audited financial statements for the fiscal year ended March 31, 2023.